Abstract
Multiparameter flow cytometry (MFC)-based clonality assessment is a powerful method of diagnosis and follow-up in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). However, the relevance of intraclonal heterogeneity in immunophenotypic studies remains poorly understood. The main objective of this work was to characterize the different immunophenotypic subclones in MGUS and MM patients and to investigate their correlation with disease stages. An 8-color MFC protocol with 17 markers was used to identify the subclones within the neoplastic compartment of 56 MGUS subjects, 151 newly diagnosed MM patients, 30 MM subjects in complete remission with detectable minimal residual disease, and 36 relapsed/refractory MM patients. Two or more clusters were observed in > 85% of MGUS subjects, 75% of stage I MM patients, and < 15% in stage III. Likewise, a significant correlation between the dominant subclone size, secondary cytogenetic features, and changes in the expression of CD27, CD44, and CD81 was detected. The loss of intraclonal equilibrium may be an important factor related with kinetics and risk of progression not well considered to date in MFC studies. The MFC strategy used in this work can provide useful biomarkers in MGUS and MM.
Journal Section:
Editor's choice
References
1.
Raja
KR
, Kovarova
L
, Hajek
R
. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders
. Br J Haematol
. 2010
May
;149
(3
):334
–51
.
[PubMed]
0007-10482.
Pérez-Persona
E
, Mateo
G
, García-Sanz
R
, Mateos
MV
, de Las Heras
N
, de Coca
AG
, et al.. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells
. Br J Haematol
. 2010
Jan
;148
(1
):110
–4
.
[PubMed]
0007-10483.
Paiva
B
, Vídriales
MB
, Pérez
JJ
, López-Berges
MC
, García-Sanz
R
, Ocio
EM
, et al.. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis
. Blood
. 2011
Mar
;117
(13
):3613
–6
.
[PubMed]
0006-49714.
Paiva
B
, Chandia
M
, Vidriales
MB
, Colado
E
, Caballero-Velázquez
T
, Escalante
F
, et al.. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma
. Blood
. 2014
Aug
;124
(8
):1300
–3
.
[PubMed]
0006-49715.
Flores-Montero
J
, Sanoja-Flores
L
, Paiva
B
, Puig
N
, García-Sánchez
O
, Böttcher
S
, et al.. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
. Leukemia
. 2017
Oct
;31
(10
):2094
–103
.
[PubMed]
0887-69246.
Arana
P
, Paiva
B
, Cedena
MT
, Puig
N
, Cordon
L
, Vidriales
MB
, et al.. Prognostic value of antigen expression in multiple myeloma: A PETHEMA/GEM study on 1,265 patients enrolled in four consecutive clinical trials
. Leukemia
. 2017
Nov
;•••
: ; [Epub ahead of print
].
[PubMed]
0887-69247.
Lisenko
K
, Schönland
S
, Hegenbart
U
, Wallenwein
K
, Braun
U
, Mai
EK
, et al.. Potential therapeutic targets in plasma cell disorders: A flow cytometry study
. Cytometry B Clin Cytom
. 2017
Mar
;92
(2
):145
–52
.
[PubMed]
1552-49498.
Brioli
A
, Melchor
L
, Cavo
M
, Morgan
GJ
. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma
. Br J Haematol
. 2014
May
;165
(4
):441
–54
.
[PubMed]
0007-10489.
Paíno
T
, Paiva
B
, Sayagués
JM
, Mota
I
, Carvalheiro
T
, Corchete
LA
, et al.. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
. Leukemia
. 2015
May
;29
(5
):1186
–94
.
[PubMed]
0887-692410.
Bolli
N
, Avet-Loiseau
H
, Wedge
DC
, Van Loo
P
, Alexandrov
LB
, Martincorena
I
, et al.. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
. Nat Commun
. 2014
;5
(1
):2997
.
[PubMed]
2041-172311.
Lohr
JG
, Stojanov
P
, Carter
SL
, Cruz-Gordillo
P
, Lawrence
MS
, Auclair
D
, et al.; Multiple Myeloma Research Consortium
. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
. Cancer Cell
. 2014
Jan
;25
(1
):91
–101
.
[PubMed]
1535-610812.
Anderson
KC
, Auclair
D
, Kelloff
GJ
, Sigman
CC
, Avet-Loiseau
H
, Farrell
AT
, et al.. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
. Clin Cancer Res
. 2017
Aug
;23
(15
):3980
–93
.
[PubMed]
1078-043213.
van Dongen
JJ
, Lhermitte
L
, Böttcher
S
, Almeida
J
, van der Velden
VH
, Flores-Montero
J
, et al.; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
. Leukemia
. 2012
Sep
;26
(9
):1908
–75
.
[PubMed]
0887-692414.
Corre
J
, Munshi
N
, Avet-Loiseau
H
. Genetics of multiple myeloma: another heterogeneity level
. Blood
. 2015
Mar
;125
(12
):1870
–6
.
[PubMed]
0006-497115.
Paiva
B
, Corchete
LA
, Vidriales
MB
, Puig
N
, Maiso
P
, Rodriguez
I
, et al.; Spanish Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Groups
. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
. Blood
. 2016
Apr
;127
(15
):1896
–906
.
[PubMed]
0006-4971© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.
